Oncolytics Biotech weakness creates buying opportunity, says RBC Capital
RBC Capital believes the recent drop in Oncolytics following the announcement of its equity financing provides an opportunity for mid to long-term investors. The firm thinks the company has several potential catalysts in upcoming quarters, while its data has continued to be encouraging. The firm maintains an Outperform rating on the stock. :theflyonthewall.com
News For ONCY From The Last 14 Days
Check below for free stories on ONCY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
